Bioequivalence Study of Crushed Elbasvir/Grazoprevir Compared to the Whole Tablet

NCT03817619 | Completed Phase 1

• 1 other identifier: UMCN-AKF 17.01
• Study Type: interventional
• Target: 11
• Locations: 1 country
• Sites: 1

Brief Summary

Elbasvir/grazoprevir (Zepatier®) is a once-daily tablet for the treatment of chronic hepatitis C virus (HCV) GT1a, 1b or 4 infection containing the NS5A inhibitor elbasvir (ELB) 50 mg and the NS3/4A protease inhibitor grazoprevir (GZR) 100 mg. For patients with swallowing difficulties, administration of whole tablets can be problematic. In addition, HCV patients that are hospitalized (at intensive care units) due to severe illness (co-infections/ liver failure) might not be able to swallow medication. Therefore it is useful to know whether it is possible to administer ELB/GZR through a different route, like a feeding tube. In daily practice, information about the safety and efficacy of crushed tablets is lacking which might result in noncompliance, interruption or discontinuation of expensive HCV therapy. However, it is not recommended to interrupt treatment because there is no evidence about the efficacy of the therapy after discontinuation (and restarting). Currently, patients and healthcare professionals are crushing tablets without information about efficacy and safety. Depending on the biopharmaceutical characteristics of a drug formulation, crushing tablets can lead to altered pharmacokinetics of drugs. It is important to know whether pharmacokinetic parameters are influenced by crushing of tablets; both a decrease and an increase in exposure may occur. A decrease of the plasma concentrations of ELB and/or GZR potentially reduces the therapeutic effect of the drugs. Higher doses or switching to other HCV-drugs might be needed. In contrast, in case a higher Cmax and/or AUC occurs there might be an increased risk of toxicity. As a result, crushing the drug is a contra-indication based on the available data. Therefore this study will be conducted to investigate whether a crushed ELB/GZR tablet is bioequivalent to ELB/GZR as a whole tablet.

Conditions

Hepatitis C; Deglutition Disorders

Outcome Measures

Primary Outcomes (1)

• Bioequivalence AUC0-72h

  Determination of elbasvir/grazoprevir AUC0-72h by noncompartmental analysis. Descriptive statistics for the plasma concentrations of elbasvir/grazoprevir at each sampling time. Descriptive statistics for each PK parameter per treatment (geometric mean + CV%). Geometric Mean Ratios and 90% confidence intervals of pharmacokinetic parameters of treatment T (Test) vs. treatment R (Reference). AUC0-72h geometric mean ratios for elbasvir and grazoprevir with a 90% Cl falling entirely within the range of 0.7 to 1.43 are considered bioequivalent.

  72 hours

Secondary Outcomes (2)

• Bioequivalence (Cmax)

  18 days

• Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])

  18 days

Study Arms (2)

Treatment R (reference)

ACTIVE COMPARATOR

Single-dose ELB/GZR as a whole tablet in a fasted state.

Drug: Zepatier whole tablet

Treatment T (test)

EXPERIMENTAL

Single-dose crushed ELB/GZR in a fasted state.

Drug: Zepatier crushed tablet

Interventions

Zepatier whole tablet DRUG

Single-dose ELB/GZR as a whole tablet in a fasted state.

Treatment R (reference)

Zepatier crushed tablet DRUG

Single-dose crushed ELB/GZR in a fasted state.

Treatment T (test)

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subject is at least 18 and not older than 55 years at screening.
• Subject does not smoke more than 10 cigarettes, 2 cigars, or 2 pipes per day for at least 3 months prior to Day 1.
• Subject weighs at least 40 kg.
• Subject has a Quetelet Index (Body Mass Index) of 18 to 30 kg/m2, extremes included.
• Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.
• Subject is in good age-appropriate health condition as established by medical history, physical examination, and electrocardiography, results of biochemistry, hematology and urinalysis testing within 4 weeks prior to Day 1. Results of biochemistry, hematology and urinalysis testing should be within the laboratory's reference ranges. If laboratory results are not within the reference ranges, the subject is included on condition that the Investigator judges that the deviations are not clinically relevant. This should be clearly recorded.
• Subject has a normal blood pressure and pulse rate, according to the Investigator's judgment.

You may not qualify if:

• Creatinine clearance below 60 mL/min.
• Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.
• Positive hepatitis B or C test
• Pregnant female (as confirmed by an hCG test performed less than 4 weeks before day 1) or breast-feeding female. Female subjects of childbearing potential without adequate contra-ception, e.g. hysterectomy, bilateral tubal ligation, (non-hormonal) intrauterine device, total abstinence, double barrier methods, or two years post-menopausal. They must agree to take precautions in order to prevent a pregnancy throughout the entire conduct of the study.
• Therapy with any drug (for two weeks preceding Day 1), except for acetaminophen (max 2 gram/day).
• Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular disorders, neurological disorders (especially seizures and migraine), psychiatric disorders, gastro-intestinal disorders, renal and hepatic disorders (clinically relevant increased ALAT/ASAT or hyperbilirubinemia), hormonal disorders (especially diabetes mellitus), coagulation disorders.
• Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.
• History of or current abuse of drugs, alcohol or solvents (positive drugs of abuse test).
• Inability to understand the nature and extent of the study and the procedures required.
• Participation in a drug study within 60 days prior to Day 1.
• Donation of blood within 60 days prior to Day 1.
• Febrile illness within 3 days before Day 1.
• Co-worker of Radboud university medical center.

Sponsors & Collaborators

• Radboud University Medical Center: lead

Study Sites (1)

RTCCS Radboudumc

Nijmegen, Netherlands

Location

Related Publications (1)

• Pijnenburg DWM, van Seyen M, Abbink EJ, Colbers A, Drenth JPH, Burger DM. Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection. J Antimicrob Chemother. 2020 Sep 1;75(9):2661-2665. doi: 10.1093/jac/dkaa230.

  PMID: 32544221 BACKGROUND

Related Links

• paper

MeSH Terms

Conditions

Hepatitis C; Deglutition Disorders

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Hepatitis, Viral, Human; Virus Diseases; Flaviviridae Infections; RNA Virus Infections; Hepatitis; Liver Diseases; Digestive System Diseases; Esophageal Diseases; Gastrointestinal Diseases; Pharyngeal Diseases; Otorhinolaryngologic Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Open-label, 2-period, randomised, cross-over, single-centre, phase I, single-dose trial in 14 healthy adult subjects. Intrasubject comparison of PK parameters after different administrations of Zepatier

Study Record Dates

• First Submitted: January 21, 2019
• First Posted: January 25, 2019
• Study Start: March 28, 2019
• Primary Completion: July 30, 2019
• Study Completion: July 30, 2019
• Last Updated: October 19, 2020

Record last verified: 2019-08

Locations

NL (1)